Analysts project the U.S. diabetes market will surge past $75 billion by 2031, driven by advanced cell therapies and continuous glucose monitoring systems transforming patient care [3]. Regenerative ...
Cipla launches Afrezza, an orally inhaled insulin powder for diabetes patients in India. A needle-free alternative to ...
As the Jonas Brothers mark 20 years, Nick Jonas reflects on two decades of living with type 1 diabetes and using music to ...
India Today on MSN
Cipla launches inhalable insulin Afrezza in India
Manufactured by Connecticut-based biopharmaceutical company MannKind Corporation, Afrezza was first launched in the United ...
Cipla has launched inhaled insulin powder in India, providing a needle-free alternative for diabetes patients. Approved by ...
Study Finds on MSN
Dad’s Microplastic Exposure May Prime Daughters For Insulin Resistance
Fathers exposed to microplastics before conception may be setting their daughters up for metabolic problems later in life.
Cipla has launched Afrezza, an inhaled rapid-acting insulin for adults with diabetes, after CDSCO approval, and plans an ...
One of them was actually with CagriSema, which failed to hit the 25% mean weight loss in phase 3 studies that management had ...
Drugmaker Cipla has launched Afrezza (insulin human) inhalation powder, the company said, about a year after the product got ...
Meet Athul, a sixth grader from Kerala who bravely manages Type 1 diabetes daily, carrying insulin and a glucometer to school ...
NDTV Profit on MSN
Cipla Launches Inhalable Insulin For Diabetes Care
The insulin inhalation powder in Afrezza is available in single-use cartridges and is delivered via an inhaler device.
Roughly half of Americans have prediabetes or diabetes, including an increasing number of children. High blood levels of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback